Skip to main content

Advertisement

SpringerLink
Log in

Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis

  • Psoriasis (J Wu, Section Editor)
  • Published:
Current Dermatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This article reviews in detail the merits and unique nature of this combination lotion and also discusses a new type of strategy for treating psoriasis topically.

Recent Findings

The combination lotion proved much more efficacious than the vehicle. Moreover, when the combination lotion was compared head-to-head with each of the components alone (halobetasol, tazarotene) and vehicle lotion, the combination was clearly more efficacious after 8 weeks. In terms of safety, the combination lotion was well tolerated by the patients. The combination lotion is also unique in that it is the only superpotent topical steroid with long-term safety data of 1 year.

Summary

Now that the FDA has approved a superpotent topical steroid containing a topical agent for unlimited “intermittent” use, compliance and treatment efficacy can be greatly improved. Due to this, the combination lotion can greatly enhance topical therapy for psoriasis and make maintenance therapy practical.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. • Sugarman JL, Gold LS, Lebwohl MG, Pariser DM, Alexander BJ, Pillai R. A Phase 2, Multicenter, double-blind, randomized, vehicle controlled clinical study to assess the safety and efficacy of a halobetasol/tazarotene fixed combination in the treatment of plaque psoriasis. J Drugs Dermatol. 2017;16(3):197–204 This study was critical in that it was one of the first studies that demonstrated that the combination lotion was significantly superior over vehicle as early as 2 weeks. Also, the combination lotion was superior to its monads and vehicle in reducing the psoriasis signs of erythema, plaque elevation, and scaling at the target lesion. At week 8, a 2-grade improvement in IGA was achieved by 54.2% of subjects for erythema, 67.8% for plaque elevation, and 64.4% for scaling.

    CAS  PubMed  Google Scholar 

  2. • Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287–93. https://doi.org/10.1016/j.jaad.2018.03.040These were the pivotal phase III studies which demonstrated that the combination lotion was associated with significant reductions in the severity of the clinical signs of psoriasis, with no safety concerns.

    Article  CAS  PubMed  Google Scholar 

  3. Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology (Basel, Switzerland). https://doi.org/10.1159/000096069.

  4. • Lebwohl MG, Sugarman JL, Gold LS, et al. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2019;80(1):282–5. https://doi.org/10.1016/j.jaad.2018.09.002This study reported the long-term safety profile of the combination lotion in participants with moderate-to-severe psoriasis when used as monotherapy over a period of 1 year. Though infrequent, AEs reported were consistent with a product containing topical corticosteroids and retinoids.

    Article  CAS  PubMed  Google Scholar 

  5. Lebwohl M, Yoles A, Lombardi K, Lou W. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998;39(3):447–50. https://doi.org/10.1016/S0190-9622(98)70323-8.

    Article  CAS  PubMed  Google Scholar 

  6. Koo J, Blum RR, Lebwohl M. A randomized, multicenter study of calcipotriene ointment and clobetasol propionate foam in the sequential treatment of localized plaque-type psoriasis: short- and long-term outcomes. J Am Acad Dermatol. 2006;55(4):637–41. https://doi.org/10.1016/j.jaad.2006.05.026.

    Article  PubMed  Google Scholar 

  7. Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol. 2004;51(2):212–6. https://doi.org/10.1016/j.jaad.2004.01.052.

    Article  PubMed  Google Scholar 

  8. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–59. https://doi.org/10.1016/j.jaad.2008.12.032.

    Article  PubMed  Google Scholar 

  9. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol. 2005;53(1 Suppl 1):S17–25. https://doi.org/10.1016/j.jaad.2005.04.027.

    Article  PubMed  Google Scholar 

  10. Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327–48.

    Article  CAS  Google Scholar 

  11. Katz HI, Prawer SE, Medansky RS, Krueger GG, Mooneye JJ, Jones ML, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica. 1991;183(4):269–74. https://doi.org/10.1159/000247698.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco, 515 Spruce Street, San Francisco, CA, 94118, USA

    Nicholas D. Brownstone, Tina Bhutani & John Koo

Authors
  1. Nicholas D. Brownstone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tina Bhutani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Koo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas D. Brownstone.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Psoriasis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brownstone, N.D., Bhutani, T. & Koo, J. Halobetasol Propionate and Tazarotene Combination Lotion 0.01%/0.045% for Psoriasis. Curr Derm Rep 10, 21–25 (2021). https://doi.org/10.1007/s13671-020-00327-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13671-020-00327-w

Keywords

Search

Navigation